Gemifloxacin: A new, potent fluoroquinolone for the therapy of lower respiratory tract infections

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 6, 2004, Pages 831-843

  File Jr , Thomas M ^a   Tillotson, Glenn S ^b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b Oscient Pharmaceuticals   (United States)

Author keywords

Acute exacerbation of chronic bronchitis; Community acquired pneumonia; Fluoroquinolone; Gemifloxacin; Respiratory tract infection; Streptococcus pneumoniae

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DIGOXIN; ERYTHROMYCIN; FERROUS SULFATE; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LIVER ENZYME; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; SUCRALFATE; TELITHROMYCIN; TETRACYCLINE; TROVAFLOXACIN; UNINDEXED DRUG;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; HEADACHE; HUMAN; IN VITRO STUDY; LIVER TOXICITY; LOWER RESPIRATORY TRACT INFECTION; MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; OUTCOMES RESEARCH; PHOTOSENSITIVITY; PREVALENCE; RASH; STREPTOCOCCUS PNEUMONIAE; TASTE DISORDER; URTICARIA; VOMITING;

EID: 9944233493     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14789072.2.6.831     Document Type: Article

References (55)

1. File TM Jr, Iannini PB. A profile of gemifloxacin, a new respiratory fluoroquinolone. Today's Therapeutic Trends 21, 415-435 (2003).
2. Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin. Infect. Dis. 26(4), 811-838 (1998).
3. Fine MJ, Smith MA, Carson CA et al. Prognosis and outcomes of patients with community acquired pneumonia. A meta-analysis J. Am. Med. Assoc. 275(2), 134-141 (1996).
4. Jokinen C, Heiskanen L, Jouvonen H et al. Microbial etiology of community acquired pneumonia in the adult population of four municipalities in eastern Finland. Clin. Infect. Dis. 32, 1141-1154 (2001).
5. File TM Jr. Community acquired pneumonia. Lancet 362, 1991-2001 (2003).
6. Brown SD, Farrell DJ. Antibacterial susceptibility among Streptococcus pneumoniae isolated from pediatric and adult patients as part of the PROTEKT US study in 2001-2002. J. Antimicrob. Chemother. 54(Suppl. 1), I23-I29 (2004).
7. Chenoweth CE, Saint S, Martinez F, Lynch JP 3rd, Fendrick AM. Antimicrobial resistance in Streptococcus pneumoniae: implications for patients with community acquired pneumonia. Mayo Clin. Proc. 75(11), 1161-1168 (2000).
8. Niederman MS, Mandell LA, Anzueto A et al. American Thoracic Society. Guidelines for the management of adults with community acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 163(7), 1730-1754 (2001).
9. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Infectious Diseases Society of America. Update of practice guidelines for the management of community acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. 37(11), 1405-1433 (2003).
10. Grossman RG. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest 112(Suppl. 6), S310-S313 (1997).
11. Hurd S, Pauwels R. Global initiative for chronic Obstructive Lung Diseases (GOLD). Pulm. Pharmacol. Ther. 15(4), 353-355 (2002 ).
12. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 108(Suppl. 2), S43-S52 (1995).
13. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating acute exacerbations of chronic bronchitis. Clin. Ther. 21, 576-591 (1999).
14. Balter MS, La Forge J, Low DE, Mandell LA, Grossman RF, Chronic Bronchitis Working Group. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Canadian Resp. J. 10, B3-B32 (2003).
15. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. J. Am. Med. Assoc. 273(12), 957-960 (1995).
16. McCrory DC, Brown C, Gelfand SE, Bach PB. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest 119(4), 1190-1209 (2001).
17. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 23(6), 932-946 (2004).
18. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN, The Alexander Project Group. The Alexander Project 1998 to 2000: susceptibility of pathogens isolated from community acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 52(2), 229-246 (2003).
19. Felmingham D, Farrell DJ, Reinert RR, Morrissey I. Antibacterial resistance among children with community acquired respiratory tract infections (PROTEKT 1999-2000) J. Infect. 48(1), 39-55 (2004).
20. Doern GV, Brown SD. Antimicrobial susceptibility among community acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-2001. J. Infect. 48(1), 56-65 (2004).
21. Gordon KA, Biedenbach DJ, Jones RN. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community acquired respiratory tract infections and hospitalized patients with pneumonia: 5-year results for the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 46(4), 285-289 (2003).
22. Chen DK, McGeer A, De Azavedo J, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341, 233-239 (1999).
23. Ho PL, Que TL, Tsang DN, Ng TY, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiple resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob. Agents Chemother. 43, 1310-1313 (1999).
24. Linares J, de la Campa AG, Pallares R. Fluoroquinolone resistance in Streptecoccus pneumoniae. N. Engl. J. Med. 341, 1546-1547 (1999).
25. Drlica K. Mechanism of fluoroquinolone action. Curr. Opin. Microbiol. 2, 504-508 (1999).
26. Davies TA, Kelly LM, Pankuch GA, Credito KL, Jacobs MR, Appelbaum PC. Antipneumococcal activities of gemifloxacin compared with those of nine other agents. Antimicrob. Agents Chemother. 44, 304-310 (2000).
27. Tillotson GS, Peterson LR. Quinolones and pneumococci. J. Antimicrob. Chemother. 45(5), 709-710 (2000).
28. Gemifloxacin mesylate (Factive®), prescribing information. Oscient Pharmaceuticals, MA, USA (2003).
29. Ball P. Quinolone generations: natural history or natural selection? J. Antimicrob. Chemother. 46, 17-24 (2000).
30. Blondeau JM, Missaghi B. Gemifloxacin: a new fluoroquinolone. Expert Opinion Pharmacother. 5(5), 1117-1152 (2004).
31. Domagala J. Structure - activity and structure-side effect relationships for the quinolone antibacterials. J. Antimicrob. Chemother. 33, 685-706 (1994).
32. Garcia I, Pascual A, Ballesta S, Joyanes P, Perea EJ. Intracellular penetration and activity of gemifloxacin in human polymorphonuclear leukocytes. Antimicrob Agents Chemother. 44, 3193-3195 (2000).
33. Seo SM, Lee SH, Choi YJ et al. Pharmacokinetics of LB20304, a new fluoroquinolone in rats and dogs. Arch. Pharmacol. Res. 19, 359-367 (1996).
34. Gee T, Andrews JM, Ashby JP, Marshall G, Wise R. Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose. J. Antimicrob. Chemother. 47, 431-434 (2001).
35. Berry V, Page R, Satterfield J, Singley C, Straub R, Woodnutt G. Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection. J. Antimicrob. Chemother. 45(Suppl. 1), 79-85 (2000).
36. Berry V, Page R, Satterfield J, Singley C, Straub R, Woodnutt G. Comparative efficacy of gemifloxacin in experimental models of pyelonephritis and wound infection. J. Antimicrob. Chemother. 45, 87-93 (2000).
37. Edelstein PH, Shinzato T, Doyle E, Edelstein MA. In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea-pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. 45, 2204-2209 (2001).
38. Cottagnoud P, Acosta F, Cottagnoud M, Tauber MG. Gemifloxacin is efficacious against penicillin-resistant and quinolone-resistant pneumocci in experimental meningitis. Antimicrob. Agents Chemother. 46, 1607-1609 (2002).
39. Smirnov A, Wellmer A, Gerber J, Maier K, Henne S, Nau R. Gemifloxacin is effective in experimental pneumococcal meningitis. Antimicrob. Agents Chemother. 44, 767-770 (2000).
40. Ball P, File TM Jr, Twynholm M, Henkel T, 061 Study Group. Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. Int. J. Antimicrob. Agents 18, 19-27 (2001).
41. Leophonte P, File TM, Feldman C. Gemifloxacin once daily for 7 days compared with amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community acquired pneumonia of suspected pneumococcal origin. Respir. Med. 98(8), 708-720 (2004).
42. File TM Jr, Schlemmer B, Garau J, Cupo M, Young C, 049 Clinical Study Group. Efficacy and safety of gemifloxacin in the treatment of community acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. J. Antimicrob. Chemother. 48, 67-74 (2001).
43. Lode H, File TM Jr, Mandell LA, Ball P, Pypstra R, Thomas M, 185 Gemifloxacin Study Group. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin. Ther. 24, 1915-1936 (2002).
44. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcome for Medicare patients with community acquired pneumonia. Arch. Intern. Med. 164, 637-644 (2004).
45. Wilson R, Schentag JJ, Ball P, Mandell LA, 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin. Ther. 24, 639-652 (2002).
46. Sethi S, Fulambarker A, Fogarty C. A randomized double-blind study comparing 5 days oral with 7 days oral levofloxacin in patients with acute exacerbations of chronic bronchitis. Respir. Med. 98(8 , 697-707 (2004).
47. Ball P, Wilson R, Mandell L, Brown J, Henkel T, 069 Clinical Study Group. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomized, double-blind comparison with trovafloxacin. J. Chemother. 13(3), 288-298 (2001).
48. Wilson R, Langan C, Ball P, Bateman K, Pypstra R, Gemifloxacin 207 Clinical Study Group. Oral gemifloxacin once daily for 5 days compared with sequential therapy with intravenous ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respir. Med. 97(3 , 242-249 (2003).
49. Halpern MT, Palmer CS, Zodet M, Kirsch J. Cost-effectiveness of gemifloxacin: results from the GLOBE study. Am. J. Health Syst. Pharm. 59(14), 1357-1365 (2002).
50. Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg. Infect. Dis. 9, 1-9 (2000).
51. Allen A, Bygate E, Clark D, Lewis A, Pay V. The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers. Int. J. Antimicrob. Agents. 16(1), 45-50 (2000).
52. Allen A, Bygate E, Faessel H, Isaac L, Lewis A. The effect of ferrous sulfate and sucralfate on the bioavailability of oral gemifloxacin in healthy volunteers. Int. J. Antimicrob. Agents. 15(4), 283-289 (2000).
53. Vousden M, Allen A, Lewis A, Ehren N. Lack of pharmacokinetic interaction between gemifloxacin and digoxin in healthy elderly volunteers. Chemotherapy 45(6), 485-490 (1999).
54. Allen A, Vousden M, Porter A, Lewis A. Effect of Maalox on the bioavailbility of oral gemifloxacin in healthy volunteers. Chemotherapy 45(6), 504-511 (1999).
55. Davy M, Allen A, Bird N, Rost KL, Fuder H. Lack of effect of gemifloxacin on the steady-state pharmacokinetics of theophylline in healthy volunteers. Chemotherapy 45(6), 478-484 (1999).